<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590108</url>
  </required_header>
  <id_info>
    <org_study_id>11/LO/2063</org_study_id>
    <nct_id>NCT01590108</nct_id>
  </id_info>
  <brief_title>The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects</brief_title>
  <acronym>EXAP</acronym>
  <official_title>The Apelin-APJ System in Idiopathic Pulmonary Arterial Hypertension and Healthy Volunteers; Tissue Location and Cardiopulmonary Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to&#xD;
&#xD;
        -  Determine blood peptide levels and investigate any tissue gradients of apelin in&#xD;
           patients with idiopathic pulmonary arterial hypertension and healthy volunteers.&#xD;
&#xD;
        -  Evaluate the effect of exogenous apelin infusion on exercise performance in healthy&#xD;
           volunteers and patients with idiopathic pulmonary arterial hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary arterial hypertension remains an enigma for physician in both diagnosis&#xD;
      and treatment. Existing biomarkers, tissue characteristics and definite treatment are&#xD;
      restricted. There are many evidences suggested that Apelin-APJ system associated with&#xD;
      Idiopathic Pulmonary Arterial Hypertension (IPAH). A comprehensive characterise circulating&#xD;
      peptide levels and investigate any tissue gradients of apelin in patients with idiopathic&#xD;
      pulmonary arterial hypertension and healthy volunteers might provide important information&#xD;
      about pathophysiologic process and diagnostic marker. In addition, first time human study to&#xD;
      assessment the effect of exogenous apelin infusion on exercise performance in healthy&#xD;
      volunteers and patients with idiopathic pulmonary arterial hypertension is essential to&#xD;
      confirm whether the relevance between animal models and clinical subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Apelin infusion on cardiopulmonary performance in healthy volunteers and patient with idiopathic pulmonary hypertension</measure>
    <time_frame>6 months</time_frame>
    <description>Characterise circulating peptide levels and investigate any tissue gradients of apelin in patients with idiopathic pulmonary arterial hypertension and healthy volunteers.&#xD;
Assess the effect of exogenous apelin infusion on exercise performance in healthy volunteers and patients with idiopathic pulmonary arterial hypertension.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Idiopathic Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Apelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will take cardiopulmonary exercise testing with receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Pyr1)apelin-13</intervention_name>
    <description>(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups</description>
    <arm_group_label>Apelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Control group:&#xD;
&#xD;
          -  Structurally normal heart by 2D Echocardiography&#xD;
&#xD;
          -  Pulmonary artery pressure &lt; 25mmHg&#xD;
&#xD;
          -  Tricuspid velocity &lt; 2.5ms-1&#xD;
&#xD;
        Inclusion Criteria for Treatment group:&#xD;
&#xD;
          -  Clinical diagnosis of Pulmonary arterial hypertension that is idiopathic, associated&#xD;
             with anorexigens associated with connective tissue disease or familial&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Mean pulmonary artery pressure &gt; 25mmHg, pulmonary capillary wedge pressure &lt; 15mmHg,&#xD;
             with normal or reduced cardiac output.&#xD;
&#xD;
        Exclusion Criteria for ALL group:&#xD;
&#xD;
          -  Bleeding diathesis (PT &gt; 14 sec to aPTT &gt; 40 sec)&#xD;
&#xD;
          -  Pregnancy, or women of child bearing potential not on adequate contraception&#xD;
&#xD;
          -  Renal or hepatic failure&#xD;
&#xD;
          -  Severe valvular heart disease&#xD;
&#xD;
          -  Left ventricular dysfunction (LVEF &lt; 40)&#xD;
&#xD;
          -  Chronic lung disease&#xD;
&#xD;
          -  Malignant arrhythmias&#xD;
&#xD;
          -  Chronic thromboembolic disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luke Sebastian Howard, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gareth D Barnes, MBChB</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College NHS trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital, Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>w12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Arterial Hypertension</keyword>
  <keyword>IPAH</keyword>
  <keyword>Apelin</keyword>
  <keyword>APJ receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

